These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36732167)

  • 1. Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Uwamino Y; Yokoyama T; Sato Y; Shibata A; Kurafuji T; Tanabe A; Noguchi M; Arai T; Ohno A; Yokota H; Namkoong H; Nishimura T; Kosaki K; Hasegawa N; Wakui M; Murata M; Matsushita H
    Vaccine; 2023 Feb; 41(9):1545-1549. PubMed ID: 36732167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Uwamino Y; Kurafuji T; Takato K; Sakai A; Tanabe A; Noguchi M; Yatabe Y; Arai T; Ohno A; Tomita Y; Shibata A; Yokota H; Yamasawa W; Namkoong H; Sato Y; Hasegawa N; Wakui M; Murata M;
    Vaccine; 2022 Jul; 40(32):4538-4543. PubMed ID: 35718591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
    Miyakawa K; Kato H; Ohtake N; Jeremiah SS; Ryo A
    J Infect Dis; 2023 Jan; 227(2):221-225. PubMed ID: 35978486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.
    Kanai D; Wakui H; Hanaoka M; Haze T; Azushima K; Shinoda S; Tsukamoto S; Taguchi S; Kinguchi S; Kanaoka T; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
    Clin Exp Nephrol; 2023 Jul; 27(7):639-647. PubMed ID: 36977892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
    Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
    J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
    Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():896151. PubMed ID: 35844588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
    J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers.
    Tamura M; Fujita R; Sato T; Sato R; Kato Y; Nagasawa M; Matsumoto T
    J Infect Chemother; 2022 Nov; 28(11):1478-1482. PubMed ID: 35921965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.
    Franzese M; Coppola L; Silva R; Santini SA; Cinquanta L; Ottomano C; Salvatore M; Incoronato M
    Front Immunol; 2022; 13():947187. PubMed ID: 36248864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
    Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
    PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers.
    Nikolova M; Todorova Y; Emilova R; Trifonova I; Gladnishka T; Petrova-Yancheva N; Chervenyakova T; Dragusheva E; Popov G; Christova I
    J Med Virol; 2022 May; 94(5):2008-2018. PubMed ID: 34997611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.
    Heftdal LD; Pérez-Alós L; Hasselbalch RB; Hansen CB; Hamm SR; Møller DL; Pries-Heje M; Fogh K; Gerstoft J; Grønbæk K; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Sabin C; Nielsen SD
    EBioMedicine; 2023 Jul; 93():104661. PubMed ID: 37331161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
    Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
    Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
    Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
    Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.